News
$SLRX.US$ Salarius Pharmaceuticals Notified By MD Anderson Cancer Center Of Grade 4 Adverse Event In Seclidemstat Clinical Trial; FDA Places Trial On Partial Clinical Hold; No New Patients Enrolled, Current Patients May Continue Treatment; Company To Support Data Analysis And Respond To FDA Queries
- 8K Filing
- 8K Filing
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
皓瓦 : GG
百富30y : runrunrun